Drug intelligence / Profile preview

BMS-820132

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-820132 is an orally active, selective, partial glucokinase activator developed by Bristol Myers Squibb for the treatment of type 2 diabetes mellitus. As a glucokinase activator, it enhances the activity of glucokinase (hexokinase 4), a key enzyme in glucose metabolism and homeostasis. Preclinical studies demonstrated promising efficacy in lowering blood glucose levels and favorable safety profiles. Clinical development included phase 1 trials to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with type 2 diabetes on metformin therapy. No further clinical development has been reported since these early-stage studies.

Other names: CHEMBL5072532CHEMBL-5072532CHEMBL 50725321001419-18-6

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on BMS-820132.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-820132.

Explore the full profile